The WISDOM trial tested a risk-based breast cancer screening plan against standard yearly mammograms in more than 28,000 women aged 40 to 74, showing risk-tailored screening can match traditional annual screening for preventing advanced cancers while shifting how often people get checked.
Researchers enrolled over 28,000 women and randomly assigned them to two different screening strategies, aiming to determine whether tailoring exams to individual risk is safe and effective. The study combined genetic data from nine key breast cancer genes with personal health factors to estimate each woman’s index risk. That risk score drove the recommended screening schedule rather than a one-size-fits-all annual visit.
High-risk participants were told to alternate between mammograms and MRI scans every six months, a more aggressive approach designed to catch fast-moving disease. Women with elevated risk were advised to continue yearly mammography and receive counseling to manage their care. Average-risk women moved to mammograms every two years, and low-risk individuals were often advised to delay screening until they either reached age 50 or their risk rose.
The headline result was reassuring: the risk-based plan did not produce more advanced cancers—stage 2B or higher—than the routine annual screening group. That suggests steering screening intensity by risk does not let dangerous cancers slip through at higher rates. However, the hope that this method would cut the total number of biopsies did not play out; biopsies remained common overall.
Digging into the numbers, women categorized as higher risk received more tests, underwent more biopsies, and had more cancers detected. Conversely, those labeled lower risk experienced fewer procedures and fewer findings. The trial effectively concentrated resources and interventions toward the people most likely to benefit.
“[The] findings suggest that risk-based breast cancer screening is a safe alternative to annual screening for women aged 40 to 74 years,” the researchers noted in the research summary. “Screening intensity matched individual risk, potentially reducing unnecessary imaging.” That official take highlights safety and the potential to pare back unneeded scans for some women.
“If you don’t measure stage 0, stage 1 or stage 2A cancers, you can’t tell whether personalized screening delays diagnosis in a way that matters for survival and treatment intensity,” Saphier, who was not involved in the study, told Fox News Digital in an interview. Her point is that without careful tracking of the earliest cancer stages, any trade-offs in timing could go unnoticed where they matter most.
More than 60% of breast cancers in the U.S. are found at stage 1 or 2A, where cure rates exceed 90%, the doctor noted. That reality is the backbone of screening rationale: finding disease early usually means simpler treatment and better outcomes. Any shift in screening must preserve that early-detection advantage if it is to be considered a real alternative.
“Mammography is not without risk — radiation exposure, false positives, anxiety and potential over-diagnosis are real and should be acknowledged,” she said. Yet she also emphasized that mammography remains the most proven method for catching cancers when they are easiest to treat. Those trade-offs are central to debates over whether to personalize screening schedules.
“Until long-term mortality data support alternative approaches, annual screening beginning at 40 for average risk women should continue,” Saphier added. “Women should be assessed for breast cancer risk by 25 years old to determine if screening should begin earlier.” Those recommendations push for caution: personalization shows promise, but broader adoption needs longer follow-up focused on survival and long-term harms.
